TACE联合重组人血管内皮抑制素介入治疗肝细胞癌临床分析

Interventionary treatment of hepatocellular carcinoma by TACE combined with recombinant human intramuscular inhibitor

目的探讨肝动脉化疗栓塞(TACE)联合重组人血管内皮抑制素介入治疗原发性肝细胞癌(HCC)的临床疗效。方法:将52例HCC患者随机分为观察组和对照组各26例,观察组给予TACE联合重组人血管内皮抑制素介入治疗,对照组单纯给予TACE治疗,比较两组的不良反应、临床疗效及治疗前后血液甲胎蛋白(AFP)水平、肝外转移等情况。结果:治疗后两组的血液AFP水平、不良反应发生率等比较,差异无统计学意义(P>0.05);观察组总有效率明显高于对照组,差异有统计学意义(P<0.05);术后1年的肝外转移发生率明显低于对照组,差异有统计学意义(P<0.01)。结论:TACE联合重组人血管内皮抑制素介入治疗HCC能提高疗效,有效地减少肿瘤肝外转移,安全有效。

Objective To explore the effect of TACE combined with endostatin on hepatocellular carcinoma（HCC）.Methods Fifty-to HCC patients were randomly assigned into the treatment group and control group with 1：1 allocation.Subjects in treatment groups were given TACE combined with endostatin,while those in control group were given TACE only.The curative effect,AFP level before and after treatment,adverse events and extrahepatic metastasis between the two groups were compared Results A higher total effective rate and lower extrahepatic metastasis rate 1 year after treatment in treatment group was observed（p0.05 and p0.01） respectively.And there were no statisticall significant differences in adverse event rate and pre-post comparison of AFP level between the two groups. Conclusion TACE combined with endostatin is effective for treatment of HCC patients.